SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is generating significant market buzz as it reclaims the $66,000 level, fueled by a Treasury department move that sparked immediate speculation regarding potential liquidity injections and monetary easing. The community is actively debating whether this breakout marks the start of a sustained rally or a temporary trap, with many traders closely monitoring $65,000 as a critical resistance point that could trigger a broader short squeeze.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares have surged significantly following positive late-stage trial results for a personalized mRNA cancer vaccine, triggering a massive short squeeze and intense retail activity. Community sentiment is deeply polarized, with bulls celebrating the breakthrough potential for oncology while bears caution against overvaluation and the risks associated with chasing such rapid gains.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant community attention as it tests key resistance levels, with many traders debating whether a breakout above $2,000 is imminent or if further consolidation is ahead. Discussions are currently dominated by speculative sentiment regarding potential regulatory updates and the long-term role of institutional inflows versus retail exhaustion.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid intense community debate over its aggressive share dilution strategy, which management is using to bolster cash reserves and prioritize the stability of its preferred stock. Investors remain sharply divided, with bulls eyeing potential upside from Bitcoin's price consolidation and institutional accumulation, while bears continue to highlight risks related to the company's complex capital structure and ongoing equity offerings.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is seeing increased investor engagement as the community debates a potential breakout, driven by aggressive share buybacks and ongoing treasury accumulation of Ethereum. Despite lingering skepticism and frustration regarding past management performance and volatile price action, many investors remain focused on the stock's MNAV expansion and the broader potential for an institutional-led crypto bull run.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as investors rally around the company's strong commercial momentum and upcoming pipeline milestones, including pivotal NSCLC data and potential guidance upgrades. The community is actively discussing the potential for a short squeeze and long-term valuation re-rating, contrasting Iovances durable TIL therapy platform with recent broader biotech sector news.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to mixed second-quarter earnings and management's commitment to a licensing-focused business model. Community discussion is dominated by intense debates over the potential of the Matrix-M adjuvant platform in oncology and frustration regarding the pace of partnership announcements for the company's combination vaccine candidates.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending as investors aggressively debate the stock's trajectory ahead of its upcoming earnings report, with community members polarized between bullish expectations of a squeeze and bearish concerns over potential post-earnings sell-offs. Discussion is dominated by chart analysis, institutional accumulation patterns, and comparisons to peers within the digital brokerage sector.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors digest news of its successful Phase 3 trial for a personalized mRNA cancer vaccine in combination with Keytruda, fueling market optimism about the future of immunotherapy. Community discourse is heavily focused on the clinical validation of mRNA platforms and Merck's strategic positioning to extend the dominance of its blockbuster drug, Keytruda.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum as investors speculate on a potential short squeeze, given that over 30% of its float is currently shorted. The stock is also gaining traction as a primary beneficiary of the broader AI-healthcare data theme, with the community actively debating whether it can maintain its recent breakout above key moving averages.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cantor⬆️ $APLS PT to $40 from $39, reiterated at an Overweight and said it thinks Empaveli C3G launch will go well. 
$NVS AZN 
$ALPMY $OCUL $EYPT REGN SRZN RHHBY 
Cantor said in its note: &quot;We reiterate Overweight rating on $APLS as GA market is stabilizing and the launch in C3G/IC-MPGN is under way. 
 
C3G patients and nephrologists face a decision on how to treat their C3 glomerulopathy diagnosis: by inhibiting C3 (with Empaveli) .... or by inhibiting &quot;FaCtOr B&quot; (woozy emoji). Never mind in addition to actually reducing C3 deposits, Empaveli also has meaningfully better efficacy, a broader label, and absence of a hyperlipidemia warning found in Fabhalta&#39;s label. Consequently, we think Empaveli C3G launch will go well.&quot;

Cantor reiterated $APLS Overweight/$39 after Apellis announced Empaveli received sNDA approval in patients 12 years or older with C3G or primary IC-MPGN.&quot; 
$NVS $AZN 
Cantor added, &quot;The label specifically includes eGFR data (showing stability) with a time series insert that&#39;s not present in Fabhalta label. 
 
C3G/IC-MPGN patients can use commercially approved pump or Empaveli injector, twice-weekly subQ administration compared to twice daily oral Fabhalta. 
 
C3G is potentially a $1B+ opportunity for Apellis in the U.S. In 2025E, we model~$4.5M (FactSet $12.4M) revenue and in 2026E ~$106M (FactSet $114.2M). 
 
We think Novartis&#39; Fabhalta launch in C3G provides a nice proof of commercial opportunity, and Empaveli can and likely will be used in a wider population (IC-MPGN, post-transplant, adolescents).&quot;

StockTwits Web

Apellis Pharmaceuticals Inc

Novartis AG

AstraZeneca PLC

Quantumup

ASTELLAS PHARMA/ADR

Ocular Therapeutix Inc

EyePoint Pharmaceuticals Inc

 PT to $40 from $39, reiterated at an Overweight and said it thinks Empaveli C3G launch will go well. 


 REGN SRZN RHHBY 
Cantor said in its note: "We reiterate Overweight rating on 

 as GA market is stabilizing and the launch in C3G/IC-MPGN is under way. 
 
C3G patients and nephrologists face a decision on how to treat their C3 glomerulopathy diagnosis: by inhibiting C3 (with Empaveli) .... or by inhibiting "FaCtOr B" (woozy emoji). Never mind in addition to actually reducing C3 deposits, Empaveli also has meaningfully better efficacy, a broader label, and absence of a hyperlipidemia warning found in Fabhalta's label. Consequently, we think Empaveli C3G launch will go well."